{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:01:07Z","timestamp":1767650467835},"reference-count":85,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Pharmacogenomics"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.2217\/pgs.14.133","type":"journal-article","created":{"date-parts":[[2015,2,25]],"date-time":"2015-02-25T10:46:00Z","timestamp":1424861160000},"page":"257-271","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":27,"title":["Targeting HER Family in\u00a0HER2-Positive Metastatic Breast Cancer: Potential Biomarkers and Novel Targeted Therapies"],"prefix":"10.1080","volume":"16","author":[{"given":"In\u00eas","family":"de Paula Costa Monteiro","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Porto, Porto, Portugal"}]},{"given":"Pedro","family":"Madureira","sequence":"additional","affiliation":[{"name":"ICBAS \u2013 Instituto de Ci\u00eancias Biom\u00e9dicas Abel Salazar, University of Porto, Porto, Portugal"},{"name":"IBMC \u2013 Instituto de Biologia Molecular e Celular, Porto, Portugal"}]},{"given":"Alessandro","family":"de Vasconscelos","sequence":"additional","affiliation":[{"name":"Clinical Research Unit, Instituto de Oncologia da Bahia, Salvador, Bahia, Brazil"},{"name":"Service of Medical Oncology, N\u00facleo de Terapia Oncol\u00f3gica, Hospital Jorge Valente, Salvador, Brazil"}]},{"given":"Daniel","family":"Humberto Pozza","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Porto, Porto, Portugal"}]},{"given":"Ramon","family":"Andrade de Mello","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Porto, Porto, Portugal"},{"name":"Department of Medical Oncology, Portuguese Oncology Institute, Porto, Portugal"},{"name":"Department of Biomedical Sciences & Medicine, School of Medicine, Campos de Gambelas, University of Algarve,\u00a0Campus de Gambelas, ala nascente, Edif\u00edcio 7, 3o. andar, 8009-135, Faro, Portugal"}]}],"member":"301","published-online":{"date-parts":[[2015,2,25]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20107"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.3798106"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/stem.160413"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/35021093"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.3.737"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevOncog.v17.i1.20"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2013.11.002"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/35052073"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.14.1.492-500.1994"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(03)00048-0"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-1872"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/16.7.1647"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1002753107"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1996.tb00603.x"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.16.10.5276"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1200105109"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0349"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2006.02403.x"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3181dbb77e"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-013-2570-6"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10911-008-9080-x"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-13-0637"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10911-008-9076-6"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-07-0369"},{"key":"e_1_3_2_27_1","first-page":"1313","article-title":"Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas","volume":"10","author":"Stuart AA","year":"1995","unstructured":"Stuart AA , Di FioreP , KrausMH . Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas . Oncogene10 , 1313 \u2013 1821 ( 1995 ).","journal-title":"Oncogene"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-0380"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1537685100"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3594"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3513"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2656"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc0509"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.01.007"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05474"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1016140108"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-3856"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq421"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70130-X"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.10.031"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1018001108"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2024"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.8197"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2696"},{"issue":"24","key":"e_1_3_2_45_1","first-page":"S5","article-title":"S5\u20131: Neoadjuvant pertuzumab (P) and trastuzumab (H): biomarker analyses of a 4-arm randomized Phase II study (NeoSphere) in patients (pts) with HER2-positive breast cancer (BC)","volume":"71","author":"Gianni L","year":"2012","unstructured":"Gianni L , BianchiniG , KiermaierAet al. S5\u20131: Neoadjuvant pertuzumab (P) and trastuzumab (H): biomarker analyses of a 4-arm randomized Phase II study (NeoSphere) in patients (pts) with HER2-positive breast cancer (BC) . Cancer Res.71 ( Suppl. 24 ), S5 \u2013 S1 ( 2012 ).","journal-title":"Cancer Res."},{"issue":"24","key":"e_1_3_2_46_1","first-page":"S5","article-title":"Biomarker analyses in CLEOPATRA: a Phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC)","volume":"72","author":"Baselga J","year":"2012","unstructured":"Baselga J , Cort\u00e9sJ , ImSet al. Biomarker analyses in CLEOPATRA: a Phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC) . Cancer Res.72 ( Suppl. 24 ), S5 \u2013 S1 ( 2012 ).","journal-title":"Cancer Res."},{"key":"e_1_3_2_47_1","volume-title":"104th Annual Meeting of the American Association for Cancer Research.","author":"Baselga J","year":"2013","unstructured":"Baselga J , VermaS , RoJet al. Relationship between tumor biomarkers (BM) and efficacy in EMILIA, a Phase III study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) . Presented at : 104th Annual Meeting of the American Association for Cancer Research.Washington, DC, USA , 6\u201310 April 2013 ."},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-013-2665-0"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0204"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.8448"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.89"},{"key":"e_1_3_2_52_1","volume-title":"ESMO 2012 Vienna.","author":"Schneeweiss A","year":"2012","unstructured":"Schneeweiss A , ChiaS , HeggRet al. Biomarker (BM) analyses of a Phase II study of neoadjuvant pertuzumab and trastuzumab with and without anthracycline (ATC)-containing chemotherapy for treatment of HER2-positive early breast cancer (BC)(TRYPHAENA) . Presented at : ESMO 2012 Vienna.Austria , 28 September\u20132 October 2012 ."},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3145"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(12)72180-9"},{"key":"e_1_3_2_55_1","volume-title":"104th Annual Meeting of the American Association for Cancer Research.","author":"Wallweber J","year":"2013","unstructured":"Wallweber J , ChennaA , RavaneraR , HuangW , StathasD , MarshallG . Profiling HER3\/ErbB3 activation in formalin-fixed, paraffin-embedded (FFPE) breast tumor samples that express high and low HER2\/ErbB2 levels using proximity-based immunoassays . Presented at : 104th Annual Meeting of the American Association for Cancer Research.Washington, DC, USA , 6\u201310 April 2013 ."},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.106906"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra043186"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(02)00097-1"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103153441101"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2639"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds232"},{"key":"e_1_3_2_62_1","unstructured":"Network NCC: NCCN clinical practice guidelines in oncology : breast cancer 2014 (Version 3.2014) . www.nccn.org"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.6618"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-009-0112-2"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1168"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-010-9415-5"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-1182"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa064320"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113216"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209124"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.8707"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-012-2003-y"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.6725"},{"key":"e_1_3_2_74_1","volume-title":"Thirty-Third Annual CTRC-AACR San Antonio Breast Cancer Symposium.","author":"Dieras V","year":"2010","unstructured":"Dieras V , HarbeckN , AlbainKet al. A Phase Ib\/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab for patients with HER2-positive, locally advanced or metastatic breast cancer: interim efficacy and safety results . Presented at : Thirty-Third Annual CTRC-AACR San Antonio Breast Cancer Symposium.San Antonio, TX, USA , 8\u201312 December 2010 ."},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.27.15_suppl.1004"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3051"},{"key":"e_1_3_2_77_1","volume-title":"104th Annual Meeting of the American Association for Cancer Research.","author":"Tyler SM","year":"2013","unstructured":"Tyler SM , VincentS , FleetCet al. AV-203, a fully humanized ERBB3 inhibitory antibody, reverses ERBB3-induced resistance to targeted therapies . Presented at : 104th Annual Meeting of the American Association for Cancer Research.Washington, DC, USA , 6\u201310 April 2013 ."},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-1198"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-0099"},{"key":"e_1_3_2_80_1","volume-title":"104th Annual Meeting of the American Association for Cancer Research.","author":"Meulendijks D","year":"2013","unstructured":"Meulendijks D , LolkemaMPJK , VoestEEet al. A first-in-human trial of RG7116, a glycoengineered monoclonal antibody targeting HER3, in patients with advanced\/metastatic tumors of epithelial cell origin expressing HER3 protein . Presented at : 104th Annual Meeting of the American Association for Cancer Research.Washington, DC, USA , 6\u201310 April 2013 ."},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604700"},{"issue":"3","key":"e_1_3_2_82_1","first-page":"582","article-title":"Antitumor activity of a novel bispecific antibody that targets the ErbB2\/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3","volume":"11","author":"McDonagh CF","year":"2012","unstructured":"McDonagh CF , HuhalovA , HarmsBDet al. Antitumor activity of a novel bispecific antibody that targets the ErbB2\/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3 . Mol. Cell. Biol.11 ( 3 ), 582 \u2013 593 ( 2012 ).","journal-title":"Mol. Cell. Biol."},{"key":"e_1_3_2_83_1","volume-title":"Thirty-Third Annual CTRC-AACR San Antonio Breast Cancer Symposium.","author":"Beeram M","year":"2010","unstructured":"Beeram M , DenlingerC , TolcherAet al. MM-111 - a novel bispecific antibody targeting HER-2\/HER-3 Z heterodimer: safety and tolerability in a first-in human Phase I\/II study in patients with refractory HER2-positive (HER-2+) cancers Presented at : Thirty-Third Annual CTRC-AACR San Antonio Breast Cancer Symposium.San Antonio, TX, USA , 8\u201312 December 2010 ."},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.79"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-2146"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2011.03.019"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0791"}],"container-title":["Pharmacogenomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/pgs.14.133","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T15:39:00Z","timestamp":1715960340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/pgs.14.133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,25]]},"references-count":85,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.2217\/pgs.14.133"],"URL":"https:\/\/doi.org\/10.2217\/pgs.14.133","relation":{},"ISSN":["1462-2416","1744-8042"],"issn-type":[{"value":"1462-2416","type":"print"},{"value":"1744-8042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgs20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgs20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-02-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}